Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199768 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL201723 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL101606 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL99862 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL100559 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL200499 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL102043 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL103499 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL102057 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL101266 | 1.00 | TSHR (0.44) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| CN-106893581-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-106892915-B | Organic compound, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-106892914-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-108101922-A | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-8940943-B2 | Cosmetic preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2601166-A1 | COSMETIC PREPARATIONS | Cognis IP Management GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131188-A1 | Cosmetic Preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2426101-A1 | Cosmetic preparations | Cognis IP Management GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012016642-A1 | COSMETIC PREPARATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-20090149584-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-2013278-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008006834-A2 | USE OF IMIDAZOLE COMPOUNDS AS PLASTICISERS | BASF SE (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007122204-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131188-A1 | Cosmetic Preparations | CYP1B1, CBR1, ACOX3 | TSHR 1074/4885THRB 3322/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.